Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status

Cope, 2007, The central role of T cells in rheumatoid arthritis, Clin Exp Rheumatol, 25, S4

Firestein, 2003, Evolving concepts of rheumatoid arthritis, Nature, 423, 356, 10.1038/nature01661

Hassan, 2011, Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity, Int J Rheum Dis, 14, 325, 10.1111/j.1756-185X.2011.01630.x

Gaber, 2013, Clinical significance of serum interleukin-6 and −174 G/C promoter polymorphism in Rheumatoid arthritis patients, The Egypt Rheum, 35, 107, 10.1016/j.ejr.2012.11.002

Gheita, 2014, Subclinical reduced G6PD activity in rheumatoid arthritis and Sjögren’s syndrome patients: relation to clinical characteristics, disease activity and metabolic syndrome, Mod Rheumatol, 24, 612, 10.3109/14397595.2013.851639

Mahdy, 2014, Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients, Bull Faculty Pharm, Cairo Univ, 52, 37, 10.1016/j.bfopcu.2014.01.002

Al-Zifzaf, 2015, FoxP3+T regulatory cells in Rheumatoid arthritis and the imbalance of the Treg/TH17 cytokine axis, The Egypt Rheumatol, 37, 218

Abaza, 2013, Deficient or abundant but unable to fight? Estimation of circulating FoxP3+ T regulatory cells and their counteracting FoxP3− in rheumatoid arthritis and correlation with disease activity, The Egypt Rheumatol, 35, 185, 10.1016/j.ejr.2013.03.005

Goldring, 2000, Pathogenesis of bone erosions in rheumatoid arthritis, Curr Opin Rheumatol, 12, 195, 10.1097/00002281-200005000-00006

Wan, 2006, Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis, J Immunol, 177, 8844, 10.4049/jimmunol.177.12.8844

Yamazaki, 2002, Expression of programmed death-1 ligands by murine T cells and APC, J Immunol, 169, 5538, 10.4049/jimmunol.169.10.5538

Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int Immunol, 19, 813, 10.1093/intimm/dxm057

Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331

Kinter, 2008, The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands, J Immunol, 181, 6738, 10.4049/jimmunol.181.10.6738

Poholek, 2010, In vivo regulation of Bcl6 and T follicular helper cell development, J Immunol, 185, 313, 10.4049/jimmunol.0904023

Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immun, 11, 141, 10.1016/S1074-7613(00)80089-8

Nishimura, 2001, Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice, Science, 291, 319, 10.1126/science.291.5502.319

Liu, 1996, The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium, Arthritis Rheum, 39, 110, 10.1002/art.1780390115

Okamoto, 2003, Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis, J Rheumatol, 30, 1157

Dong, 2003, Costimulating aberrant T cell responses by B7–H1 autoantibodies in rheumatoid arthritis, J Clin Invest, 111, 363, 10.1172/JCI16015

Aletaha, 2010, Rheumatoid arthritis classification criteria an American College of Rheumatology/European League Against Rheumatism, Arthritis Rheum, 62, 2569, 10.1002/art.27584

Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum, 38, 44, 10.1002/art.1780380107

Bruce, 2003, The Stanford health assessment questionnaire (HAQ): a review of its history, issues, progress, and documentation, J Rheumatol, 30, 167

Van der Heijde, 1999, How to read radiographs according to the Sharp/van der Heijde method, J Rheumatol, 26, 743

Westergren, 1921, Studies of suspension stability of the blood in pulmonary tuberculosis, Am Rev Tuberc, 14, 94

Lin, 2004, Association of a programmed death-1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus, Arthritis Rheum, 50, 770, 10.1002/art.20040

Wang, 2007, Polymorphisms of genes for programmed cell death-1 ligands in patients with rheumatoid arthritis, J Clin Immunol, 27, 563, 10.1007/s10875-007-9113-z

Gowthaman, 2010, T cell help to B cells in germinal centers: putting the jigsaw together, Int Rev Immunol, 29, 403, 10.3109/08830185.2010.496503

Dai, 2014, The PD-1/PD-Ls pathway and autoimmune diseases, Cell Immunol, 290, 72, 10.1016/j.cellimm.2014.05.006

Song, 2011, Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1, J Immunother, 34, 297, 10.1097/CJI.0b013e318210ed0e

Kuipers, 2006, Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation, Eur J Immunol, 36, 2472, 10.1002/eji.200635978

Greisen, 2014, Increased soluble programmed death-1(sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis, Scand J Rheumatol, 43, 101, 10.3109/03009742.2013.823517

Kerlan-Candon, 2001, Specific overexpression of rheumatoid arthritis associated HLA-DR alleles and presentation of low-affinity peptides, Arthritis Rheum, 44, 1281, 10.1002/1529-0131(200106)44:6<1281::AID-ART220>3.0.CO;2-2

Fontenot, 2003, Foxp3 programs the development and function of CD4 CD25 regulatory T cells, Nat Immunol, 4, 330, 10.1038/ni904

Li, 2014, Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis, Inflammation, 37, 116, 10.1007/s10753-013-9718-8